Erythropoietin in the Treatment of Cancer

Henke, Michael

doi:10.1159/000084038

Cited by 3 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall, the safety profile was comparable between the two treatment groups, including drug-related AEs. There continues to be discussion [9,[18][19][20] on the relative safety of ESA treatment in oncology.…”

Section: Safetymentioning

confidence: 99%

HX575, Recombinant Human Epoetin Alfa, for the Treatment of Chemotherapy-Associated Symptomatic Anaemia in Patients with Solid Tumours

2009

View full text Add to dashboard Cite

Background: Recombinant human epoetin alfa, HX575, is the first biosimilar erythropoiesis-stimulating agent (ESA) with European marketing authorisation. The primary objective of this double-blind, randomised, multicentre study was to assess the efficacy and safety of HX575 in treating chemotherapy-associated symptomatic anaemia in patients with solid tumours. Patients and Methods: The patients (n = 114) were treated with HX575 or active control (epoetin alfa) at 150 IU/kg body weight 3 times weekly for 12 weeks, increased to 300 IU/kg body weight 3 times weekly if the haemoglobin/reticulocyte increase was insufficient after 4 or 8 weeks. Results: With HX575, haemoglobin increased by ≥20 g/l in 62% (37/60 patients). The confidence interval (48.2%, 73.9%) was entirely above the pre-defined 30% threshold. Both groups showed similar results for safety profiles and secondary efficacy parameters. Transfusion requirements were 32% (19/60) (HX575) and 38% (13/34) (epoetin alfa). Conclusions: In treating chemotherapy-associated symptomatic anaemia in patients with solid tumours, the biosimilar ESA, HX575, is efficacious with a safety profile as expected for the therapeutic area.

show abstract

Section: Safetymentioning

confidence: 99%

HX575, Recombinant Human Epoetin Alfa, for the Treatment of Chemotherapy-Associated Symptomatic Anaemia in Patients with Solid Tumours

2009

View full text Add to dashboard Cite

show abstract

Brown tumours of the tibia and second metacarpal bone in a woman with severe vitamin D deficiency

et al. 2015

View full text Add to dashboard Cite

SUMMARYBrown tumours caused by vitamin D deficiency are rare. Most cases are caused by primary hyperparathyroidism, and are rarely caused by secondary hyperparathyroidism in cases of renal failure. We present a case of Brown tumours of the tibia and second metacarpal bone in a 50-year-old woman who had a low dietary intake of vitamin D and had worn a veil for most of her adult life. The Brown tumours were caused by vitamin D deficiency and secondary hyperparathyroidism. The patient improved on treatment with vitamin D3 and calcium supplements. This is a rare case and the first, to our knowledge, with a Brown tumour of the tibia caused by vitamin D deficiency due to decreased dietary intake and decreased exposure to sunlight. The course of treatment and investigations of the patient are described. BACKGROUND

show abstract